Companies/Natera, Inc.

Company profile

Natera, Inc.

NASDAQ: NTRA · Healthcare · Medical - Diagnostics & Research

PublicHQ Austin, CACIK 0001604821Reports USD

#105 of 1,394 Healthcare companies by revenue73rd-percentile growth

EA Score

75B+

FH 74DQ 73GM 78SS 80

v0.1 · 65/100 weight · provisional

↑ market scale, Altman-Z · ↓ listing tenure, operating margin

Methodology →

Revenue TTM

$2.5B

Rev growth YoY (TTM)

+36.6%

Net income (FY)

-$208.2M

Employees

4,424

Market cap

$40.0B

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$2.3B$2.3B2025

Net income-$208.2M-$208.2M2025

Operating income-$309.9M-$309.9M2025

Total assets$2.4B$2.4B2025

Liabilities$685.9M$685.9M2025

Equity$1.7B$1.7B2025

Revenue trend

FY2019 – FY2025 · USD

$77.9M

FY19

$302.3M

FY19

$391.0M

FY20

$625.5M

FY21

$820.2M

FY22

$1.1B

FY23

$1.7B

FY24

$2.3B

FY25

Revenue by segment

Filed disclosures · FY2025

By product

Product100%

Licensing and other0%

By geography

United States98%

Europe, Middle East, India, and Africa1%

Americas, excluding U.S.0%

Asia Pacific and Other0%

The read

Natera, Inc. booked $2.3B in FY2025 revenue, growing 36% year over year — faster than most Healthcare companies we track, at a -9.0% net margin.

Peers · Healthcare

Revolution Medicines, Inc.52D Alnylam Pharmaceuticals, Inc.79B+Agilent Technologies, Inc.84B+Medline Inc.53D

Key facts

CEOSteven Leonard Chapman

SectorHealthcare

IndustryMedical - Diagnostics & Research

HeadquartersAustin, CA

ExchangeNASDAQ: NTRA

Employees4,424

IPO date2015-07-01

Latest filings

8-K2026-06-16 8-K2026-06-05 10-Q2026-05-08 8-K2026-05-07 DEF 14A2026-04-23 8-K2026-04-01 10-K2026-02-27 8-K2026-02-26

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.